Long-Term Survival in Patients With Advanced Melanoma

被引：3

作者：

van Not, Olivier J. ^{[1
,2
]}

van den Eertwegh, Alfons J. M. ^{[3
]}

Jalving, Hilde ^{[4
]}

Bloem, Manja ^{[1
,5
,6
]}

Haanen, John B. ^{[7
]}

van Rijn, Rozemarijn S. ^{[8
]}

Aarts, Maureen J. B. ^{[9
]}

van den Berkmortel, Franchette W. P. J. ^{[10
]}

Blank, Christian U. ^{[7
,11
]}

Boers-Sonderen, Marye J. ^{[12
]}

de Groot J. W. B., Jan Willem ^{[13
]}

Hospers, Geke A. P. ^{[4
]}

Kapiteijn, Ellen ^{[14
]}

Leeneman, Brenda ^{[15
,16
]}

Piersma, D. ^{[17
]}

Stevense-den Boer, Marion ^{[18
]}

van der Veldt, Astrid A. M. ^{[19
]}

Vreugdenhil G., Gerard ^{[20
]}

Wouters, Michel W. J. M. ^{[1
,5
,6
]}

Blokx, Willeke A. M. ^{[21
]}

Suijkerbuijk, Karijn P. M. ^{[2
]}

机构：

[1] Dutch Inst Clin Auditing, Sci Bur, Leiden, Netherlands

[2] Univ Utrecht, Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands

[3] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

[4] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands

[5] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands

[6] Netherlands Canc Inst, Dept Surg Oncol, Amsterdam, Netherlands

[7] Netherlands Canc Inst, Dept Mol Oncol & Immunol, Amsterdam, Netherlands

[8] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[9] Maastricht Univ Med Ctr, GROW Sch Oncol & Dev Biol, Dept Med Oncol, Maastricht, Netherlands

[10] Zuyderland Med Ctr Sittard, Dept Med Oncol, Sittard Geleen, Netherlands

[11] Netherlands Canc Inst, Dept Med Oncol & Immunol, Amsterdam, Netherlands

[12] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands

[13] Isala Oncol Ctr, Isala, Zwolle, Netherlands

[14] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands

[15] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Dept Hlth Technol Assessment, Rotterdam, Netherlands

[16] Erasmus Univ, Erasmus Ctr Hlth Econ Rotterdam, Rotterdam, Netherlands

[17] Med Spectrum Twente, Dept Internal Med, Enschede, Netherlands

[18] Amphia Hosp, Dept Internal Med, Breda, Netherlands

[19] Erasmus MC, Dept Med Oncol & Radiol & Nucl Med, Rotterdam, Netherlands

[20] Maxima Med Ctr, Dept Internal Med, Eindhoven, Netherlands

[21] Univ Utrecht, Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands

来源：

JAMA NETWORK OPEN | 2024年 / 7卷 / 08期

关键词：

METASTATIC MELANOMA; FOLLOW-UP; IPILIMUMAB; PEMBROLIZUMAB; OUTCOMES;

D O I：

10.1001/jamanetworkopen.2024.26641

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IMPORTANCE Long-term survival data from clinical trials show that survival curves of patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs) gradually reach a plateau, suggesting that patients have a chance of achieving long-term survival. OBJECTIVE To investigate long-term survival in patients with advanced melanoma treated with ICIs outside clinical trials. DESIGN, SETTING, AND PARTICIPANTS Cohort study using prospectively collected data from the nationwide Dutch Melanoma Treatment Registry, including patients in the Netherlands with advanced melanoma treated with first-line ICIs from 2012 to 2019. Data were analyzed from January to September 2023. EXPOSURES Patients were treated with first-line ipilimumab-nivolumab, antibodies that target programmed cell death (anti-PD-1), or ipilimumab. MAIN OUTCOMES AND MEASURES Progression-free survival (PFS) and melanoma-specific survival were analyzed, and a Cox proportional hazards model was used to investigate factors associated with PFS after reaching partial response (PR) or complete response (CR). RESULTS A total of 2490 patients treated with first-line ICIs were included (median [IQR] age, 65.0 [55.3-73.0] years; 1561 male patients [62.7%]). Most patients had an Eastern Cooperative Oncology Group Performance Status of 1 or lower (2202 patients [88.5%]) and normal lactate dehydrogenase levels (1715 patients [68.9%]). PFS for all patients was 23.4% (95% CI, 21.7%-25.2%) after 3 years and 19.7% (95% CI, 18.0%-21.4%) after 5 years. Overall survival for all patients was 44.0% (95% CI, 42.1%-46.1%) after 3 years and 35.9% (95% CI, 33.9%-38.0%) after 5 years. Patients with metastases in 3 or more organ sites had a significantly higher hazard of progression after reaching PR or CR (adjusted hazard ratio, 1.37; 95% CI, 1.11-1.69). CONCLUSIONS AND RELEVANCE This cohort study of patients with advanced melanoma treated with ICIs in clinical practice showed that their survival reached a plateau, comparable with patients participating in clinical trials. These findings can be used in daily clinical practice to guide long-term surveillance strategies and inform both physicians and patients regarding long-term treatment outcomes.

引用

页数：13

共 50 条

[1] LONG-TERM SURVIVAL OF PATIENTS WITH ADVANCED MELANOMA TREATED SECOND LINE WITH IPILIMUMAB
Lee, D.
Pericleous, L.
Lebmeier, M.
Winn, B.
Batty, A.
Nikoglou, T.
ANNALS OF ONCOLOGY, 2012, 23 : 370 - 370
[2] Long-term outcome of patients with advanced melanoma
Parolin, V.
Nortilli, R.
Strina, C.
Sabbioni, R.
Sava, T.
Cetto, G. L.
EJC SUPPLEMENTS, 2007, 5 (04): : 400 - 401
[3] Long-term survival in patients with advanced immunodeficiency
Chene, G
Easterbrook, PJ
Juszczak, E
Yu, LM
Pocock, SJ
Gazzard, BG
AIDS, 1997, 11 (02) : 209 - 216
[4] Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine
Hersh, E.
Weber, J.
Powderly, J.
Pavlik, A.
Nichol, G.
Yellin, M.
Cranmer, L.
Urba, W.
O'Day, S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[5] Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
Ismail, Rawa K.
Suijkerbuijk, Karijn P. M.
de Boer, Anthonius
van Dartel, Maaike
Hilarius, Doranne L.
Pasmooij, A. M. G.
van Zeijl, Michiel C. T.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
Blank, Christian U.
Boers-Sonderen, Marye J.
de Groot, Jan W. B.
Haanen, John B. A. G.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Rozemarijn S.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Westgeest, Hans
van den Eertwegh, Alfons J.
Wouters, Michel W. J. M.
MELANOMA RESEARCH, 2022, 32 (06) : 460 - 468
[6] Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
McDermott, David
Lebbe, Celeste
Hodi, F. Stephen
Maio, Michele
Weber, Jeffrey S.
Wolchok, Jedd D.
Thompson, John A.
Balch, Charles M.
CANCER TREATMENT REVIEWS, 2014, 40 (09) : 1056 - 1064
[7] Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Topalian, Suzanne L.
Sznol, Mario
McDermott, David F.
Kluger, Harriet M.
Carvajal, Richard D.
Sharfman, William H.
Brahmer, Julie R.
Lawrence, Donald P.
Atkins, Michael B.
Powderly, John D.
Leming, Philip D.
Lipson, Evan J.
Puzanov, Igor
Smith, David C.
Taube, Janis M.
Wigginton, Jon M.
Kollia, Georgia D.
Gupta, Ashok
Pardoll, Drew M.
Sosman, Jeffrey A.
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) : 1020 - +
[8] Long-Term Survival Shown for Advanced Melanoma Patients Treated with PD-1 Inhibitor
Printz, Carrie
CANCER, 2016, 122 (20) : 3100 - 3101
[9] Long-term survival of real-world advanced melanoma patients treated with targeted therapy
Ismail, R.
de Boer, A.
van Dartel, M.
Hilarius, D.
van Zeijl, M.
van den Eertwegh, F.
Aarts, M.
Van den Berkmortel, F.
Boers-Sonderen, M.
de Groot, J. W. B.
Haanen, J. B. A. G.
Hospers, G. A. P.
Kapiteijn, E.
Piersma, D.
van Rijn, R.
Suijkerbuijk, K. P. M.
ten Tije, A. J.
Van der Veldt, A. A. M.
Vreugdenhil, G.
Wouters, M.
ANNALS OF ONCOLOGY, 2020, 31 : S745 - S746
[10] LONG-TERM SURVIVAL IN PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE PANCREAS
JAFFREY, IS
CANCER TREATMENT REPORTS, 1980, 64 (12): : 1391 - 1392

← 1 2 3 4 5 →